Entera Bio Ltd (ENTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Entera Bio Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Entera Bio Ltd (ENTX) has returned -42.78% so far this year and -34.71% over the past 12 months.

Based on dividend-adjusted daily data since Jun 28, 2018, ENTX's average daily return is +0.12%, while the average monthly return is +0.84%. At this rate, your investment would double in approximately 6.9 years.

Historically, 38% of months were positive and 62% were negative. The best month was Mar 2021 with a return of +129.5%, while the worst month was Dec 2018 at -42.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ENTX closed higher 42% of trading days. The best single day was Mar 11, 2021 with a return of +152.5%, while the worst single day was May 21, 2020 at -23.0%.

Entera Bio Ltd has an annualized alpha of 25.17%, beta of 0.49, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 29, 2018.

• This stock participated in 162.62% of S&P 500 Index downside but only 48.11% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.49 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ENTX ranks 23 for risk / return — below 23% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Entera Bio Ltd (ENTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Entera Bio Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Entera Bio Ltd was 92.75%, occurring on Nov 11, 2022. The portfolio has not yet recovered.

The current Entera Bio Ltd drawdown is 83.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Entera Bio Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Entera Bio Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.